Liver doctor survey on predicting liver cancer in cured hepatitis C patients
Part of Cancer clinical trials.
This study asks liver doctors (hepatologists) about their knowledge and views on new ways to predict liver cancer in hepatitis C patients who were cured with antiviral pills. Your answers can help improve cancer screening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a hepatologist (liver specialist).
- You have at least one year of experience caring for people with hepatitis C.
- You are not a general doctor or non-liver specialist.
- You will fill out the entire survey.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what factors predict liver cancer (HCC) in people with HCV-related cirrhosis after they've been cured of hepatitis C. It compares those who developed HCC soon after cure to those who didn't, to find clues for better monitoring.
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
This study uses patient data to build a model that predicts the chance of developing liver cancer in people with chronic hepatitis B who are on antiviral treatment. It aims to help doctors identify who might need closer monitoring.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This study looks at how well the HepatoPredict tool predicts outcomes for people with liver cancer who had a liver transplant or surgery to remove the tumor. The researchers are checking if the tool was accurate by reviewing data from at least 5 years after the procedure.
This study uses non-invasive tests, like scans or blood tests, to predict how well people with liver cancer (hepatocellular carcinoma, or HCC) will do after curative treatment. It may help doctors better understand your condition without needing invasive procedures.
Hear when a new Non-invasive Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.